NurExone Biologic

NRX.V

Biotechnology · Healthcare

Price

C$0.49

+0.00 (+0.00%)

Market Cap

C$36.0M

Exchange

Toronto Stock Exchange Ventures

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

NurExone Biologic is a small biotechnology company focused on developing treatments for spinal cord injuries and other conditions that damage the nervous system. Its lead product, ExoPTEN, uses tiny biological particles called exosomes to deliver therapy directly to injured nerve tissue, with the goal of helping patients regain movement or sensation after serious injuries. The company is in the early clinical stage, meaning its treatments are still being tested and have not yet been approved for sale.

NurExone earns no significant revenue yet, as it is pre-commercial and relies on equity financing and grants to fund its research. The company is based in Israel and Canada, and its technology is built around a proprietary exosome platform, which it considers a key differentiator in the emerging field of exosome-based drug delivery. The main risk is typical for early-stage biotech: clinical trials may fail, regulatory approval is uncertain, and the company will need continued funding to advance its pipeline.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Insider Activity

24.3%ownership

Insiders own a meaningful stake in the company

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

no trend

Data not available

Operating Margin

N/A

no trend

Data not available

ROCE

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

no trend

Data not available

EPS YoY

N/A

no trend

Data not available

EPS Consistency

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

no trend

Data not available

FCF Margin

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

no trend

Data not available

Interest Cover

N/A

no trend

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/A

no trend

Data not available

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial